Senseonics(US:SENS) Globenewswire·2025-10-06 20:05Core Insights - Senseonics Holdings, Inc. reported preliminary unaudited revenue of approximately $8.1 million for Q3 2025, marking a 91% increase compared to Q3 2024, driven by a 160% growth in new patients in the U.S. [2][10] - The company announced a reverse stock split at a ratio of 1:20, effective October 17, 2025, which will reduce the number of outstanding shares from approximately 816 million to about 41 million [3][5]. Financial Performance - The preliminary revenue of $8.1 million in Q3 2025 reflects significant growth, attributed to increased investments in direct-to-consumer marketing and the highest number of new patient starts in the company's history occurring in September 2025 [2][4]. - The company anticipates that the reverse stock split will not affect stockholders' ownership percentages significantly, aside from minor adjustments due to cash payments for fractional shares [6]. Business Strategy - Senseonics is focusing on enhancing its direct-to-consumer marketing efforts, which have led to increased awareness and adoption of its Eversense 365 continuous glucose monitoring system [4][8]. - The decision to bring the sales and marketing organization in-house is expected to bolster the company's ability to drive revenue and meet patient expectations [4]. Product Information - The Eversense CGM systems are designed for long-term glucose monitoring, with the Eversense 365 capable of continuous measurement for up to 365 days [9]. - The systems utilize a small sensor implanted under the skin, which communicates with a smart transmitter to provide real-time glucose data to users [8].